ABSTRACT
BACKGROUND: Patients with inflammatory breast cancer (IBC) have a high risk of central nervous system metastasis (mCNS). The purpose of this study was to quantify the incidence of and identify risk factors for mCNS in patients with IBC. METHODS: The authors retrospectively reviewed patients diagnosed with IBC between 1997 and 2019. mCNS-free survival time was defined as the date from the diagnosis of IBC to the date of diagnosis of mCNS or the date of death, whichever occurred first. A competing risks hazard model was used to evaluate risk factors for mCNS. RESULTS: A total of 531 patients were identified; 372 patients with stage III and 159 patients with de novo stage IV disease. During the study, there were a total of 124 patients who had mCNS. The 1-, 2-, and 5-year incidence of mCNS was 5%, 9%, and 18% in stage III patients (median follow-up: 5.6 years) and 17%, 30%, and 42% in stage IV patients (1.8 years). Multivariate analysis identified triple-negative tumor subtype as a significant risk factor for mCNS for stage III patients. For patients diagnosed with metastatic disease, visceral metastasis as first metastatic site, triple-negative subtype, and younger age at diagnosis of metastases were risk factors for mCNS. CONCLUSIONS: Patients with IBC, particularly those with triple-negative IBC, visceral metastasis, and those at a younger age at diagnosis of metastatic disease, are at significant risk of developing mCNS. Further investigation into prevention of mCNS and whether early detection of mCNS is associated with improved IBC patient outcomes is warranted.
Subject(s)
Breast Neoplasms , Central Nervous System Neoplasms , Inflammatory Breast Neoplasms , Humans , Female , Inflammatory Breast Neoplasms/epidemiology , Inflammatory Breast Neoplasms/therapy , Incidence , Retrospective Studies , Breast Neoplasms/epidemiology , Breast Neoplasms/therapy , Central Nervous System Neoplasms/epidemiology , Central Nervous System Neoplasms/therapy , Central Nervous System/pathologyABSTRACT
CONTEXT: PEComas (tumors showing perivascular epithelioid cell differentiation) of the pancreas are exceedingly rare. CASE REPORT: We herein report on a 60-year-old female who noticed a bulge in her right upper quadrant while exercising. Subsequent multidetector-row CT scan showed a 3.5 cm well-defined, encapsulated, hypovascular, solid tumor in the body of the pancreas. Endoscopic ultrasound demonstrated a mixed hypo- and hyper-echoic, well-defined, heterogeneous tumor. CONCLUSIONS: Although three pancreatic PEComas (sugar tumors) have been described previously, to the best of our knowledge, this is the first report of a pancreatic PEComa with illustration of its multidetector-row CT and endoscopic ultrasound features in the radiological literature.
